Probiomics

Executive Summary

Probiomics is an Italian biotechnology service company founded in 2005 as a spin-off from the University of Rome 'Tor Vergata'. The company specializes in end-to-end multi-omics data production and bioinformatic analysis, covering genomics, transcriptomics, proteomics, and epigenomics. Its mission is to simplify biological complexity by transforming multi-omics data into actionable insights for research and discovery. As a private company with no disclosed funding rounds, valuation, or stage information, Probiomics operates in the competitive microbiome and metabolic research service space. The company's profile lacks details on revenue, employee count, or commercial products, suggesting it may be an early-stage or niche player primarily serving academic and pharmaceutical clients in Italy and potentially beyond. Its long history since 2005 indicates operational stability, but the absence of public milestones or partnerships limits visibility into its growth trajectory. The company has not been actively profiled or contacted, and its website score has not been assessed, reflecting a low profile in the broader biotech ecosystem. Despite this, Probiomics' focus on multi-omics integration aligns with growing industry demand for comprehensive data solutions in precision medicine and microbiome research. However, without clear differentiators or recent news, the company's near-term prospects remain uncertain.

Upcoming Catalysts (preview)

• Q4 2026Announcement of strategic collaboration with academic or pharmaceutical partners in microbiome research40% success
• Q1 2027Expansion of service offerings into new omics technologies (e.g., metabolomics or single-cell omics)30% success
• 2027Disclosure of funding round or government grant to support technology development or international expansion25% success